Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Location status: Recruiting
Location contact
Stephen Bruehl, PhD
CONTACT
NCT Number: NCT06083480
This is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (OS); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (glycine + N-acetyl-cysteine(GlyNAC)) reduces oxidative stress and chronic post surgical pain (CPSP) in patients undergoing total knee arthroplasty (TKA).
Interested in participating?
Request Info50 year and older
All sexes
Interventional
Phase 4
Nashville, Tennessee, 37212, United States
Location status: Recruiting
Stephen Bruehl, PhD
CONTACT
One of the most common surgical procedures performed in older adults is total knee arthroplasty (TKA), with an estimated 1 million TKAs performed annually in the United States. TKA directly addresses the pathology underlying knee joint pain and mobility limitations resulting from osteoarthritis. For most patients, TKA is effective for pain reduction and increasing function. However, a subgroup of 15-20% of TKA patients report unsatisfactory long-term pain outcomes well after postsurgical healing has occurred despite technical success of the procedure. Chronic postsurgical pain (CPSP) following TKA has been reported to be worse than the preoperative pain in 7% of TKA patients at up to 4-years. A potential biological mechanism is perioperative oxidative stress (OS),
The proposed project seeks to confirm the mechanistic role of OS in post-TKA CPSP and test the hypothesis that a perioperative intervention to reduce OS may reduce risk for CPSP post-TKA. This is a prospective randomized controlled trial that will assess preoperative, perioperative, and long-term oxidative stress (OS); pain; and functional outcomes over a 12 month period and test the hypothesis that a potent antioxidant intervention (GlyNAC) reduces OS and CPSP in patients undergoing total knee arthroplasty (TKA).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
Other names: GlyNAC
Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
Time frame: Baseline to 6 months post TKA (approximately 7 months)
Mean within participant changes in NRS intensity ratings of worst pain in past 24 hours of measurement at 6 months post TKA. The score is a rating of current acute pain using a 0-100 numeric rating scale (NRS) (0 = "no pain" and 100 = "worst possible pain").
Time frame: Baseline to 6 weeks and 12 months post TKA (13 months)
Mean within participant changes in NRS intensity ratings of worst pain in past 24 hours of measurement. The score is a rating of current acute pain using a 0-100 numeric rating scale (NRS) (0 = "no pain" and 100 = "worst possible pain")
Time frame: Baseline to 6 weeks, 6 months and 12 months post TKA (13 months)
Mean within participant changes in NRS intensity ratings of average pain in past 24 hours of measurement. The score is a rating of current acute pain using a 0-100 numeric rating scale (NRS) (0 = "no pain" and 100 = "worst possible pain").
Time frame: Baseline to 6 weeks, 6 months and 12 months post TKA (13 months)
Mean within participant changes in NRS intensity ratings of least pain in past 24 hours of measurement. The score is a rating of current acute pain using a 0-100 numeric rating scale (NRS) (0 = "no pain" and 100 = "worst possible pain").
Time frame: Baseline to 6 weeks, 6 months and 12 months post TKA (13 months)
Mean within participant changes in McGill Pain Questionnaire-2 (MPQ-2) ratings of knee pain for average pain over past week of measurement. The MPQ-2 score ranges from 0-10 where 0 represents no pain and 10 represents the most intense pain.
Time frame: Baseline to 6 weeks, 6 months and 12 months post TKA (13 months)
Mean within participant changes in KOOS-JR ratings to assess movement evoked pain and functional limitations. Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health.
Time frame: Baseline to 6 weeks, 6 months and 12 months post TKA (13 months)
Mean within participant changes in PROMIS Short Form V1.0 - Pain Interference 8a scale to assess pain-related life interference over the week preceding assessments. This is an 8 item questionnaire with scores ranging from 0-40. 0 indicates no pain interference and 40 indicates the highest level of pain interference.
Time frame: Post-TKA discharge to 6 weeks, 6 months and 12 months post-TKA (12 months)]
Number of prescribed opioid pills used since hospital discharge following TKA. This is based on a combination of prescribed postsurgical opioid amounts and number of refills recorded in the electronic health record combined with pill counts conducted at each in-person post-TKA follow-up assessment.
Time frame: 6 weeks, 6 months and 12 months post-TKA (12 months)
Number of days opioids were used in the past week at each in-person post-TKA follow-up assessment.
Time frame: Baseline to 4 week pre-TKA assessment, and 6 weeks, 6 months and 12 months post TKA (13 months)
Changes in mean IsoP/IsoF levels from initial pre-intervention baseline. This is a measure of oxidative stress and is a mechanistic marker of the effects of the study antioxidant intervention (GlyNAC).
Time frame: Baseline to 4 week pre-TKA assessment, and 6 weeks, 6 months and 12 months post TKA (13 months)
Changes in mean glutathione levels from initial pre-intervention baseline. This is a measure of antioxidant capacity and is a mechanistic marker of the effects of the study antioxidant intervention (GlyNAC).
Contact information is provided by the study sponsor or research team.
Gail Mayo, RN
CONTACT
Stephen Bruehl, Ph.D.
CONTACT
Vanderbilt University Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07630337
Arthritis, Joint Diseases
Buenos Aires, Argentina
View Trial DetailsNCT06145516
Arthritis, Dyssomnias
Uppsala, Uppland, Sweden
View Trial DetailsNCT07517159
Arthritis, Joint Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07047040
Arthritis, Joint Diseases
Asyut, Asyut Governorate, Egypt
View Trial Details